GB8328917D0
(en)
*
|
1983-10-28 |
1983-11-30 |
Fisons Plc |
Blood substitute
|
USRE34271E
(en)
*
|
1984-06-27 |
1993-06-01 |
University Of Iowa Research Foundation |
Production of alpha-alpha cross-linked hemoglobins in high yield
|
JP2962731B2
(ja)
*
|
1986-11-10 |
1999-10-12 |
バイオピュアー、コーポレーション |
超純枠半合成代用血液
|
US5189146A
(en)
*
|
1987-05-05 |
1993-02-23 |
Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence |
Pasteurizable, freeze-driable hemoglobin-based blood substitute
|
GB8710598D0
(en)
*
|
1987-05-05 |
1987-06-10 |
Star Medical Diagnostics Ltd |
Hemoglobin based blood substitute
|
US5449759A
(en)
*
|
1987-05-16 |
1995-09-12 |
Somatogen, Inc. |
Hemoglobins with intersubunit desulfide bonds
|
WO1989005358A1
(en)
|
1987-11-30 |
1989-06-15 |
University Of Iowa Research Foundation |
Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
US5164272A
(en)
*
|
1987-12-03 |
1992-11-17 |
Chloride Silent Power Limited |
Alkali metal cell
|
CA1338244C
(en)
*
|
1988-08-17 |
1996-04-09 |
Xiang-Fu Wu |
Purification of hemoglobin and methemoglobin by bioselective elution
|
US5128452A
(en)
*
|
1989-04-19 |
1992-07-07 |
Baxter International Inc. |
Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate
|
US5844090A
(en)
*
|
1994-05-09 |
1998-12-01 |
Somatogen, Inc. |
Modified hemoglobin-like compounds
|
US6150506A
(en)
*
|
1989-05-10 |
2000-11-21 |
Baxter Biotech Technology Sarl |
Modified hemoglobin-like compounds and methods of purifying same
|
US5545727A
(en)
*
|
1989-05-10 |
1996-08-13 |
Somatogen, Inc. |
DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
|
US5599907A
(en)
*
|
1989-05-10 |
1997-02-04 |
Somatogen, Inc. |
Production and use of multimeric hemoglobins
|
ES2204926T3
(es)
|
1989-05-10 |
2004-05-01 |
Baxter Biotech Technology S. .R.L. |
Procedimiento de preparacion de hemoglobina y derivados de hemoglobina a partir de manipulacion de bacterias y levaduras.
|
US6828125B1
(en)
*
|
1989-05-10 |
2004-12-07 |
Baxter Biotech Technology, S.A.R.L. |
DNA encoding fused di-alpha globins and use thereof
|
US5439882A
(en)
*
|
1989-12-29 |
1995-08-08 |
Texas Tech University Health Sciences Center |
Blood substitute
|
ES2082971T3
(es)
*
|
1990-03-14 |
1996-04-01 |
Univ Toronto |
Esteres de fosfato de acilo y modificacion de proteinas con los mismos.
|
US6172039B1
(en)
|
1990-04-16 |
2001-01-09 |
Apex Bioscience, Inc. |
Expression of recombinant hemoglobin and hemoglobin variants in yeast
|
US5352773A
(en)
*
|
1990-08-06 |
1994-10-04 |
Baxter International Inc. |
Stable hemoglobin based composition and method to store same
|
US5248766A
(en)
*
|
1990-08-17 |
1993-09-28 |
Baxter International Inc. |
Oxirane-modified hemoglobin based composition
|
ATE119917T1
(de)
*
|
1990-11-29 |
1995-04-15 |
Upjohn Co |
Mit imidoester quer-vernetzte hämoglobinzusammensetzungen.
|
US5250665A
(en)
*
|
1991-05-31 |
1993-10-05 |
The University Of Toronto Innovations Foundation |
Specifically β-β cross-linked hemoglobins and method of preparation
|
US5334705A
(en)
*
|
1991-08-15 |
1994-08-02 |
Duke University |
Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
|
EP0611306B1
(de)
*
|
1991-11-08 |
1998-07-08 |
Somatogen, Inc. |
Hämoglobine als arzneimittelabgabesystem
|
US5334706A
(en)
*
|
1992-01-30 |
1994-08-02 |
Baxter International |
Administration of low dose hemoglobin to increase perfusion
|
US5900477A
(en)
*
|
1992-01-30 |
1999-05-04 |
Baxter International, Inc. |
Use of hemoglobin in the treatment of hemorrhagic shock
|
US5980954A
(en)
|
1992-02-07 |
1999-11-09 |
Vasogen Ireland Limited |
Treatment of autoimmune diseases
|
GB9617611D0
(en)
*
|
1996-08-22 |
1996-10-02 |
Vasogen Inc |
Treatment of autoimmune disease
|
US6669965B2
(en)
|
1992-02-07 |
2003-12-30 |
Vasogen Ireland Limited |
Method of treating atherosclerosis
|
US5591457A
(en)
*
|
1992-02-07 |
1997-01-07 |
Vasogen Inc |
Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
|
US5344393A
(en)
*
|
1992-02-28 |
1994-09-06 |
Alliance Pharmaceutical Corp. |
Use of synthetic oxygen carriers to facilitate oxygen delivery
|
US5290919A
(en)
*
|
1992-08-28 |
1994-03-01 |
The University Of Maryland Baltimore |
Hemoglobin intramolecularly cross-linked with trivalent reagents
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
US5650156A
(en)
*
|
1993-02-22 |
1997-07-22 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of nutriceuticals and compositions useful therefor
|
US5665382A
(en)
*
|
1993-02-22 |
1997-09-09 |
Vivorx Pharmaceuticals, Inc. |
Methods for the preparation of pharmaceutically active agents for in vivo delivery
|
US5387672A
(en)
*
|
1993-03-02 |
1995-02-07 |
The University Of Maryland At Baltimore |
Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
|
US5840851A
(en)
*
|
1993-07-23 |
1998-11-24 |
Plomer; J. Jeffrey |
Purification of hemoglobin
|
US5578564A
(en)
*
|
1993-07-23 |
1996-11-26 |
Somatogen, Inc. |
Nickel-free hemoglobin and methods for producing such hemoglobin
|
TW381022B
(en)
*
|
1993-08-16 |
2000-02-01 |
Hsia Jen Chang |
Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
|
US5741893A
(en)
*
|
1993-08-16 |
1998-04-21 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5767089A
(en)
*
|
1993-08-16 |
1998-06-16 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5840701A
(en)
*
|
1993-08-16 |
1998-11-24 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5804561A
(en)
*
|
1993-08-16 |
1998-09-08 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5824781A
(en)
*
|
1993-08-16 |
1998-10-20 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5807831A
(en)
*
|
1993-08-16 |
1998-09-15 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US5725839A
(en)
*
|
1993-08-16 |
1998-03-10 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
|
US5817632A
(en)
*
|
1993-08-16 |
1998-10-06 |
Hsia; Jen-Chang |
Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
|
US6140071A
(en)
*
|
1994-01-27 |
2000-10-31 |
Somatogen, Inc. |
Proteins with mutations to decrease N-terminal methylation
|
US6242417B1
(en)
|
1994-03-08 |
2001-06-05 |
Somatogen, Inc. |
Stabilized compositions containing hemoglobin
|
US5631219A
(en)
*
|
1994-03-08 |
1997-05-20 |
Somatogen, Inc. |
Method of stimulating hematopoiesis with hemoglobin
|
US6458762B1
(en)
|
1994-03-28 |
2002-10-01 |
Baxter International, Inc. |
Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
|
US5895810A
(en)
*
|
1995-03-23 |
1999-04-20 |
Biopure Corporation |
Stable polymerized hemoglobin and use thereof
|
JPH10501823A
(ja)
*
|
1995-04-10 |
1998-02-17 |
バクスター、インターナショナル、インコーポレイテッド |
クモ膜下出血の治療における架橋ヘモグロビンの使用
|
US5865784A
(en)
|
1995-06-07 |
1999-02-02 |
Alliance Pharmaceutical Corp. |
Method of hemodilution facilitated by monitoring oxygenation status
|
US5733869A
(en)
*
|
1995-10-06 |
1998-03-31 |
Baxter International, Inc. |
Therapeutic administration of hemoglobin in cardiac arrest
|
US6054427A
(en)
*
|
1997-02-28 |
2000-04-25 |
The Regents Of The University Of California |
Methods and compositions for optimization of oxygen transport by cell-free systems
|
US5814601A
(en)
*
|
1997-02-28 |
1998-09-29 |
The Regents Of The University Of California |
Methods and compositions for optimization of oxygen transport by cell-free systems
|
US6180598B1
(en)
|
1999-10-07 |
2001-01-30 |
Deanna J. Nelson |
Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
|
US6670323B1
(en)
|
1999-11-12 |
2003-12-30 |
Baxter International, Inc. |
Reduced side-effect hemoglobin compositions
|
DE10031742A1
(de)
*
|
2000-06-29 |
2002-01-17 |
Sanguibio Tech Ag |
Verfahren zur Herstellung künstlicher Sauerstoffträger aus kovalent vernetzten Hämoglobinen mit verbesserten funktionellen Eigenschaften durch Vernetzung in Anwesenheit chemisch nicht reagierender Effektoren der Sauerstoffaffinität der Hämoglobine
|
DE10059720A1
(de)
*
|
2000-11-30 |
2002-06-06 |
Roche Diagnostics Gmbh |
Verwendung intramolekular kovalent vernetzter Proteine als Bindepartner in Immunoassays
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
EP1894573A3
(de)
|
2002-01-11 |
2013-06-12 |
Sangart, Inc. |
Verfahren und Zusammensetzungen für den Sauerstofftransport mit hoher Sauerstoffaffinität
|
US20050164915A1
(en)
|
2002-04-01 |
2005-07-28 |
Sangart, Inc. |
Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
|
EP1472280A4
(de)
*
|
2002-01-11 |
2005-09-21 |
Sangart Inc |
Verfahren und zusammen setzungen zum sauerstofftransport, umfassend einen sauerstoffträger und ein kristalloid in einer hypertonen lösung
|
AU2003207503A1
(en)
*
|
2002-01-11 |
2003-07-30 |
Sangart, Inc. |
Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
|
US20030153491A1
(en)
*
|
2002-01-11 |
2003-08-14 |
Winslow Robert M. |
Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
|
DE60309300T3
(de)
*
|
2002-03-20 |
2011-02-24 |
Elan Pharma International Ltd. |
Nanopartikelzusammensetzungen von angiogeneseinhibitoren
|
JP3912206B2
(ja)
*
|
2002-07-05 |
2007-05-09 |
株式会社日立製作所 |
筒内直接燃料噴射装置用燃料ポンプ
|
US7135554B1
(en)
|
2004-01-27 |
2006-11-14 |
Biopure Corporation |
Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
|
ES2347805T3
(es)
*
|
2004-08-31 |
2010-11-04 |
Sangart, Inc. |
Metodos para aumentar la estabilidad hemodinamica usando composiciones que transportan oxigeno.
|
EP2026824A2
(de)
*
|
2006-05-09 |
2009-02-25 |
The United States Of America As Represented By the Sectretary of the Navy |
Multifunktionsblutersatz
|
US7759306B2
(en)
*
|
2006-05-16 |
2010-07-20 |
Simoni Jan S |
Methods of treating acute blood loss
|
US8273857B2
(en)
*
|
2009-09-22 |
2012-09-25 |
Jen-Chang Hsia |
Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
|
US7989593B1
(en)
|
2010-05-27 |
2011-08-02 |
Bing Lou Wong |
Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
|
US8048856B1
(en)
|
2010-06-23 |
2011-11-01 |
Billion King, Ltd. |
Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
|
US7932356B1
(en)
|
2010-06-23 |
2011-04-26 |
Bing Lou Wong |
Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
|
US8084581B1
(en)
|
2011-04-29 |
2011-12-27 |
Bing Lou Wong |
Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
|
US20130052232A1
(en)
|
2011-08-31 |
2013-02-28 |
Bing Lou Wong |
Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
|
WO2014179793A1
(en)
|
2013-05-03 |
2014-11-06 |
Washington University |
Blood substitute composition and method of use
|
US9814759B2
(en)
|
2014-07-02 |
2017-11-14 |
Cheer Global Ltd. |
Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
|